Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

Phase 4

Completed

• Conditions: Aging; Diabetes Mellitus, Type 2; PreDiabetes; Overweight and Obesity
• Interventions: Behavioral: Lifestyle Counseling; Drug: Semaglutide Injectable Product

• Registration Number: NCT05786521
• Lead Sponsor: The University of Texas Health Science Center at San Antonio

Brief Summary

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-03-02
• Study First Submitted QC: 2023-03-14
• Study First Posted: 2023-03-27
• Study Start: 2023-04-01
• Primary Completion: 2024-05-20
• Study Completion: 2024-05-20
• Status Verified: 2025-04
• Results First Submitted: 2025-04-02
• Results First Submitted QC: 2025-04-22
• Last Update Submitted: 2025-04-22
• Results First Posted: 2025-05-04
• Last Update Posted: 2025-05-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Older than 65
• Have prediabetes or diabetes
• BMI ≥ 27.0 kg/m2
• Living independently (not in assisted living or nursing home)

Exclusion Criteria

• Have heart disease
• Have liver disease
• Smoke

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Lifestyle intervention	Lifestyle Counseling	Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program
Semaglutide and lifestyle intervention	Semaglutide Injectable Product	Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks.
Semaglutide and lifestyle intervention	Lifestyle Counseling	Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks.

Primary Outcome Measures

Name	Time	Method
Lean Body Mass Change	Baseline to 20 weeks	Determine if there is any change in lean body mass

Trial Locations

Locations (1)

UT Health San Antonio; 🇺🇸 San Antonio, Texas, United States